Mirvetuximab soravtansine-gynx for the treatment of adult patients with FRα–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC) where the monoclonal antibody is a chimeric IgG1 that targets folate receptor alpha (FRα). The antibody is linked to a small molecule, DM4 (also known as soravtansine or ravtansine), a microtubule inhibitor by a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death, and diffuse to nearby cells causing further cell death. FRα is a receptor that is overexpressed on the surface epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and non-small-cell lung cancers.
Patients seeking to buy mirvetuximab soravtansine online in India often explore treatment eligibility, safety information, and regulated access pathways before starting therapy.
The most common adverse reactions include vision impairment, pneumonitis, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin.
The cytotoxic and genotoxic component DM4 can be toxic to actively dividing cells, suggesting its potential to cause embryotoxicity and teratogenicity. Advise patients of potential risk to fetus.
Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose.
Advise females to use effective contraception during treatment and for 7 months after the last dose.
Safety and effectiveness of mirvetuximab have not been established in pediatric patients.
No clinically meaningful differences in efficacy or safety were observed in geriatric patients compared to younger patients. No dosage adjustment of mirvetuximab is recommended for patients with mild to moderate renal or mild hepatic impairment. The effect of severe renal impairment or end-stage renal disease on mirvetuximab is unknown. Avoid use of mirvetuximab in patients with moderate or severe hepatic impairment.
Pricing and Availability
Mirvetuximab Soravtansine (Elahere) is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels.
As this is a prescription-only treatment, the price quotation for mirvetuximab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly.
The cost of mirvetuximab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements.
Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients in importing mirvetuximab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step-from verifying documents to final delivery.
Information regarding mirvetuximab soravtansine price in India is generally provided after prescription review and verification of medical documents.
Access
As mirvetuximab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines by helping procure them under the Named Patient Supply (NPS) route.
Requests to Buy Elahere Online in India are commonly associated with access to targeted therapies for eligible ovarian cancer patients.
Each mirvetuximab soravtansine-gynx injection carton contains one single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of clear to slightly opalescent, colorless sterile solution.
Availability of mirvetuximab soravtansine 100 mg/20 mL online in India is subject to prescription validation and applicable import regulations.
Import Process
-
Submit a request for your medicine:
Patients or caregivers can share their prescription and treatment details to initiate the request.
-
Apply through Form 12A
An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
-
Document verification
All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
-
Import permission
Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
-
Sourcing the medicine
Our sourcing team coordinates with authorized international suppliers to find the best available price of mirvetuximab soravtansine in India, ensuring product authenticity before finalizing the purchase. Patients looking to Buy Mirvetuximab Soravtansine in India often evaluate supplier authenticity, regulatory compliance, and import support services.
-
Medicine delivery
After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.
Required Documents
To enable the import of mirvetuximab to India, patients must provide:
- A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
- Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
- Government-issued ID and proof of residence of the patient.
- Import permit (if applicable).
Queries related to Buy Elahere 200 mg/2.5 mL Online in India are generally addressed through prescription-based procurement channels.
The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of mirvetuximab from approved international sources such as the USA, Canada, Europe, or Australia.
Access to Buy Elahere in India is typically facilitated through compliant import pathways designed for eligible patients requiring specialized therapies. To better understand these treatment-related adverse effects and their management, read our detailed guide on Elahere Side Effects: Eye, Lung and Nerve Risks Explained.
Through this process, patients can import mirvetuximab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. For pricing details or to request assistance in accessing mirvetuximab, visit 24/7QualityMeds.com.
